Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak

Vaccine

Volumn 30, Issue 49, 2012, Pages 7052-7058

  Abedi, Glen R ^a   Mutuc, Jeffry D ^a   Lawler, Jacqueline ^d   Leroy, Zanie C ^b   Hudson, Jean M ^d   Blog, Debra S ^e   Schulte, Cynthia R ^e   Rausch Phung, Elizabeth ^e   Ogbuanu, Ikechukwu U ^c   Gallagher, Kathleen ^a   Kutty, Preeta K ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Orange County Department of Health   (United States)

^e NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Adverse event; MMR; Mumps; Outbreak; Vaccine

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADVERSE DRUG REACTION; ARTHRALGIA; ARTICLE; DIZZINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EPIDEMIC; FAINTNESS; FEVER; HEALTH SURVEY; HUMAN; INFORMATION RETRIEVAL; INJECTION SITE PAIN; INJECTION SITE SWELLING; MUMPS; MYALGIA; PHYSICIAN; PRIORITY JOURNAL; PUBLISHING; RASH; SELF REPORT; SKIN REDNESS; THROMBOCYTOPENIA; URTICARIA; WHEEZING;

ADOLESCENT; CHILD; DISEASE OUTBREAKS; DRUG TOXICITY; FEMALE; HUMANS; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; NEW YORK; QUESTIONNAIRES;

EID: 84869094289     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.053     Document Type: Article

References (26)

1. American Academy of Pediatrics Mumps. Red book: 2009 report of the committee on infectious diseases 2009, 468-472. American Academy of Pediatrics, Elk Grove Village, IL. 28th ed. L.K. Pickering, C.J. Baker, D.W. Kimberlin, S.S. Long (Eds.).
2. Strebel P.M., Papania M.J., Dayan G.H., Halsey N.A. Measles vaccine. Vaccines 2008, 363-434. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
3. Centers for Disease Control and Prevention. Recommendations and guidelines: 2011 child & adolescent immunization schedules for persons aged 0-6 years, 7-18 years, and catch-up schedules. Available at: [accessed 20.01.12]. http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm.
4. Maynard J.E., Shramek G., Noble G.R., Deinhardt F., Clark P. Use of attenuated live mumps virus vaccine during a virgin soil epidemic of mumps on St. Paul Island, Alaska. Am J Epidemiol 1970, 92:301-306.
5. Wharton M., Cochi S.L., Hurcheson R.H., Bistowish J.M., Schaffner W. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988, 158(6):1253-1260.
6. Mossong J., Bonert C., Wecherding P., Oppl M., Reichert P., Evenl J., et al. Mumps outbreak among the military in Luxembourg in 2008: epidemiology and evaluation of control measures. Euro Surveill 2009, 14(February (7)).
7. Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, et al. The impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak: Pediatrics, in press.
8. Fescharek R., Quast U., Maass G., Merkle W., Schwarz S. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects. Vaccine 1990, 8:446-456.
9. Peltola H., Heinonen O.P. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1986, 1(April (8487)):939-942.
10. Virtanen M., Peltola H., Paunio M., Heinonen O.P. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 2000, 106(November (5)):E62.
11. örtqvist A., Blennow M., Carlsson R.-M., Hanson L., Lindqvist L., Magnusson M., et al. Vaccination of children - a systematic review. Acta Paed 2010, 99(Suppl. S461).
12. Vaccine Adverse Event Reporting System. Centers for Disease Control and Prevention and the Food and Drug Administration. Available from: [accessed 11.10.11]. http://vaers.hhs.gov/about/index.
13. Stokes J., Weibel R.E., Villarejos V.M., Arguedas J.A., Buynak E.B., Hilleman M.R. Trivalent combined measles-mumps-rubella vaccine: findings in clinical-laboratory studies. J Am Med Assoc 1971, 218(1):57-61.
14. Lee H., Kim H.W., Cho H.K., Park E.A., Choi K.M., Kim K.H. Reappraisal of MMR vaccines currently used in Korea. Pediatrics International 2011, 53(3):374-380.
15. Gatchalian S., Cordero-Yap L., Lu-Fong M., Soriano R., Ludan A., Chitour K., et al. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Southe Asian J Trop Med Public Health 1999, 30(3):511-517.
16. Lee C.Y., Tang R.B., Huang F.Y., Tang H., Huang L.M., Bock H.L. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Int J Infect Dis 2002, 6(3):202-209.
17. Stuck B., Stehr K., Bock H.L. Concomitant administration of varicella vaccine with combined measles: mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002, 20(2):113-120.
18. Usonis V., Bakasenas V., Kaufhold A., Chitour K., Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles: mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999, 18(1):42-48.
19. Usonis V., Bakasenas V., Chitour K., Clemens R. Comparative study of reactogenicity and immunogenicity of new and established measles: mumps and rubella vaccines in healthy children. Infection 1998, 26(4):222-226.
20. Chen R.T., Moses J.M., Markowitz L.E., Orenstein W.A. Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine 1991, 9(5):297-299.
21. Gothefors L., Bergstrom E., Backman M. Immunogenicity and reactogenicity of a new measles: mumps and rubella vaccine when administered as a second dose at 12y of age. Scand J Infect Dis 2001, 33(7):545-549.
22. Dos Santos B.A., Ranieri T.S., Bercini M., Schermann M.T., Famer S., Mohrdieck R., et al. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Rev Panam Salud Publica 2002, 12(4):240-246.
23. LeBaron C.W., Bi D., Sullivan B.J., Beck C., Gargiullo P. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006, 118(4):1422-1430.
24. Kemmeren J.M., van der Maas N.A., de Melker M.E. Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children. Eur J Pediatr 2010, 170(3):339-345.
25. Syncope after vaccination - United States, January 2005-July 2007. MMWR 2008, 57(17):457-460.
26. Varricchio F., Iskander J., DeStefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 2004, 23:287-294.